AI Article Synopsis

  • * Results showed a 72.2% rate of collarette elimination and a 77.8% rate of mite eradication by day 42, with significant reductions in mean collarette grade and mite density.
  • * Participants tolerated the treatment well, experiencing only mild and temporary adverse effects, indicating that the topical solution is a promising option for managing blepharitis.

Article Abstract

To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with blepharitis. Eighteen adults with blepharitis, defined as >10 collarettes on the upper lid and/or mite density of ≥1.5 mites per lash (upper and lower), were treated bid for 42 days with the topical lotilaner ophthalmic solution, 0.25%. Contact lens wear, artificial eyelashes, and lid structural abnormalities were among the exclusion criteria. No other antibacterial, antiparasitic, or anti-inflammatory treatment or lid hygiene products were permitted. One eye of each patient was selected for analysis and assessed on day 7, 14, 28, and 42. Collarettes were graded at each visit, and mite density was evaluated by microscopy at each visit except day 7. Outcome measures were collarette elimination (≤2 lashes with collarettes) and mite eradication (0 mites). Drop tolerability, adverse events, visual acuity, and slit-lamp biomicroscopy were assessed. Collarette elimination was achieved in 13/18 participants (72.2%) by day 42. Mean collarette grade (upper lid) declined from 3.56 ± 0.17 to 0.28 ± 0.11. Mite eradication was achieved in 14/18 participants (77.8%) by day 42. Mean mite density decreased from 2.63 ± 0.39 to 0.12 ± 0.08 mites/lash. Participants reported good tolerability. Adverse events were mild and transient and did not result in treatment discontinuation. Six weeks of at-home topical therapy with the lotilaner ophthalmic solution, 0.25%, was effective in eliminating the most common objective signs of blepharitis, with a collarette elimination rate of 72% and mite eradication in 78% of eyes by day 42. ISRCTN registration #: 24398865.

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2021.0011DOI Listing

Publication Analysis

Top Keywords

collarette elimination
16
mite eradication
16
lotilaner ophthalmic
16
ophthalmic solution
16
topical lotilaner
12
solution 025%
12
mite density
12
upper lid
8
tolerability adverse
8
adverse events
8

Similar Publications

Article Synopsis
  • Demodex blepharitis is a condition caused by Demodex mites that affects the eyelids and may require specialized treatments, as current options might not work effectively.
  • A systematic review analyzed five studies to assess the efficacy of 0.25% lotilaner ophthalmic solution in treating this condition, focusing on its ability to reduce mite populations and inflammation.
  • Results indicated that lotilaner significantly improves eyelid conditions, eradicating mites and reducing symptoms, outperforming placebo in curing related issues like collarette and erythema.
View Article and Find Full Text PDF

Topical ivermectin 1.0% cream in the treatment of ocular demodicosis.

Cont Lens Anterior Eye

February 2024

School of Optometry, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom; School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. Electronic address:

Article Synopsis
  • Ocular demodicosis can severely affect eye health, and this study explored the use of topical ivermectin 1.0% cream to treat it, given its effectiveness for similar issues in rosacea.
  • The research involved analyzing patient records, with 75 participants receiving nightly applications of the cream over three months, and assessments were made before treatment and at two follow-up appointments.
  • Results showed significant improvements, with marked reductions in signs of demodicosis, including fewer lash collarettes and signs of Demodex, indicating that ivermectin is effective for this condition, though further studies are needed for better management.
View Article and Find Full Text PDF

Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies.

Eye Contact Lens

August 2023

Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY.

Article Synopsis
  • Demodex blepharitis is a common eyelid disease affecting about 25 million Americans, caused by Demodex mites that can lead to mechanical damage, bacterial infection, and inflammation.
  • Risk factors include older age, rosacea, and diabetes, with symptoms like redness, dryness, discomfort, and the presence of collarettes, which are indicative of the condition.
  • Multiple management options exist, but none are FDA approved; however, a recent clinical trial suggests that lotilaner ophthalmic solution could effectively treat the disease by eradicating the Demodex mites and reducing symptoms.
View Article and Find Full Text PDF

Purpose: To obtain consensus on blepharitis (DB) treatment using a modified Delphi panel process.

Methods: Literature search identified gaps in knowledge surrounding treatment of DB. Twelve ocular surface disease experts comprised the Expert Panel on Treatment and Eyelid Health (DEPTH).

View Article and Find Full Text PDF
Article Synopsis
  • * Results showed a 72.2% rate of collarette elimination and a 77.8% rate of mite eradication by day 42, with significant reductions in mean collarette grade and mite density.
  • * Participants tolerated the treatment well, experiencing only mild and temporary adverse effects, indicating that the topical solution is a promising option for managing blepharitis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!